Should You Buy Emergent BioSolutions Inc (EBS) At This PE Ratio? Fri, 24 Nov 2017 21:55:16 +0000 Emergent BioSolutions Inc (NYSE:EBS) is currently trading at a trailing P/E of 20.6x, which is lower than the industry average of 26.9x. While EBS might seem like an attractive stockRead More...
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : November 23, 2017 Thu, 23 Nov 2017 12:16:34 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Emergent BioSolutions, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up Thu, 09 Nov 2017 17:39:05 +0000 Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
ETFs with exposure to Emergent BioSolutions, Inc. : November 8, 2017 Wed, 08 Nov 2017 22:59:50 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Emergent BioSolutions, Inc. Here are 5 ETFs with the largest exposure to EBS-US. Comparing the performance and risk of Emergent BioSolutions, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut Wed, 08 Nov 2017 17:21:05 +0000 Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat Wed, 08 Nov 2017 14:53:02 +0000 Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.